Transdermal delivery of mitochondrial-targeted hydrogen sulphide donor, AP39 protects against 6-hydroxydopamine-induced mitochondrial dysfunction

Abstract

Hydrogen sulphide (H 2S) is an important gaseous signalling molecule with emerging roles as a neuroprotectant. The objective of this study was to investigate the feasibility of transdermal delivery of mitochondrial-targeted H 2S donor, AP39 whilst investigating the ability of permeated AP39 on abrogating 6-hydroxydopamine (6-OH-dop)-induced mitochondrial dysfunction, as a model of Parkinson's disease, established in human neuroblastoma cells, SHSY-5Y. Aqueous hypromellose gels (5% w/v) were prepared with up to 10% v/v propylene glycol (PG) with 0.002% w/w AP39. AP39 permeation from formulations across excised murine skin into PBS was quantified over 24 h using HPLC-UV detection. Media was collected and applied to a microvasculature blood–brain-barrier (BBB) model to evidence AP39 permeability. Following, the permeate was applied to neuroblastoma cells SHSY-5Y to evidence its therapeutic potential in modulating the mitochondrial bioenergetics and antioxidant in response to 6-OH-dop-induced mitochondrial dysfunction. The presence of PG in gel formulations significantly increased the cumulative amount of AP39 permeated across murine skin over 24 h from 24.40 ± 2.39 % to 48.59 ± 2.93 %. Conditioned media applied to a microvasculature BBB model observed AP39 permeation across the barrier and H 2S release. Finally, permeated AP39 enhanced parameters of mitochondrial bioenergetics in SHSY-5Y exposed to 6-OH-dop. Moreover, permeated AP39 abrogated mitochondrial-specific reactive oxygen species generation induced by 6-OH-dop. These findings demonstrate transdermal delivery of AP39 may provide a promising alternative to deliver this mitochondrial-targeted H 2S donor and this approach allows the potential to cross the BBB reaching CNS organs in the treatment of neurodegenerative conditions such as Parkinson's disease. Moreover, our observations show that gels prepared with 10% v/v PG have the potential for use in conditions requiring rapid H 2S delivery whereas gels without PG have potential for therapy requiring sustained H 2S delivery.

Publication DOI: https://doi.org/10.1016/j.ejpb.2023.09.004
Divisions: College of Health & Life Sciences > Aston Medical School
College of Health & Life Sciences
College of Health & Life Sciences > School of Biosciences
College of Health & Life Sciences > Aston Medical School > Translational Medicine Research Group (TMRG)
College of Health & Life Sciences > School of Biosciences > Cellular and Molecular Biomedicine
Additional Information: Copyright © 2023, Elsevier. This accepted manuscript version is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International https://creativecommons.org/licenses/by-nc-nd/4.0/ Funding Information: This work was supported by the Royal Society Grant - Round 1 2021 (RGS\R1\221169) and by the Sir Halley Stewart Trust (Ref number 2728).
Uncontrolled Keywords: Transdermal drug delivery,Mitochondrial bioenergetics,Neurodegenerative conditions,Sustained release,Hydrogen sulphide donors
Publication ISSN: 1873-3441
Last Modified: 20 Jun 2024 07:34
Date Deposited: 21 Sep 2023 08:29
Full Text Link:
Related URLs: https://www.sci ... 2370?via%3Dihub (Publisher URL)
http://www.scop ... tnerID=8YFLogxK (Scopus URL)
PURE Output Type: Article
Published Date: 2023-10-01
Published Online Date: 2023-09-04
Accepted Date: 2023-09-03
Submitted Date: 2023-06-09
Authors: Marwah, Mandeep Kaur (ORCID Profile 0000-0003-4881-003X)
Manhoosh, Bahareh
Shokr, Hala
Al Tahan, Mohamad Anas
Stewart, Roderick
Iqbal, Mohammed
Sanchez, Lorena Diaz
Abdullah, Sewa
Ahmad, Shakil (ORCID Profile 0000-0002-9294-0475)
Wang, Keqing (ORCID Profile 0000-0001-6239-6344)
Rana, Karan Singh
Sanchez-Aranguren, Lissette (ORCID Profile 0000-0002-4663-5752)

Download

[img]

Version: Accepted Version

Access Restriction: Restricted to Repository staff only until 4 September 2024.

License: Creative Commons Attribution Non-commercial No Derivatives


Export / Share Citation


Statistics

Additional statistics for this record